Taxus “Peri-approval” Trial Offers Postmarket Study Model – Zuckerman
This article was originally published in The Gray Sheet
Executive Summary
FDA is encouraging PMA sponsors to file a continued-access protocol for a long-term trial that will meet postmarket study requirements following a device's approval
You may also be interested in...
FDA Pushes Faster Post-Approval Study Starts In Drug-Eluting Stent Guidance
FDA's March 26 1draft guidance on nonclinical and clinical studies of drug-eluting coronary stents is the first device guidance to recommend that sponsors begin post-market studies before their device is approved
FDA Pushes Faster Post-Approval Study Starts In Drug-Eluting Stent Guidance
FDA's March 26 1draft guidance on nonclinical and clinical studies of drug-eluting coronary stents is the first device guidance to recommend that sponsors begin post-market studies before their device is approved
Industry Reps Cite Pitfalls In FDA’s New Approach To Postapproval Studies
The recent shift of responsibility for device condition-of-approval studies to the FDA's Office of Surveillance & Biometrics could result in more elaborate and burdensome study requirements if device firms are not careful, speakers warned at this year's Regulatory Affairs Professionals Society annual meeting